Skip to content

Lung Cancer

US Focus Meeting 2026


📍 Sheraton Grand Nashville Downtown, 623 Union St, Nashville, TN 37219

🗓️ May 1-2, 2026


Dear Colleagues and Friends,

We are delighted to extend our warmest invitation to the Lung Cancer Focus Meeting 2026, to be held on May 1 - 2, 2026.

Centered around the theme “Updating Knowledge & Clinical Practice in 2026” this meeting provides pivotal collaboration aimed at advancing Lung Cancer research and patient treatment.

This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts. Engage in riveting presentations, participate in thought-provoking debates and roundtable discussions, and connect with peers at informal social gatherings.

Chairs of Lung Cancer US Focus Meeting 2026:

Charu-Aggarwal-1

Charu Aggarwal, MD, MPH, FASCO
She, her, hers
University of Pennsylvania, Philadelphia, PA

Stephen-Liu-1

Stephen Liu, MD
Georgetown Lombardi Comprehensive Cancer Center, Washington, DC


Supporters to be announced...
Interested in supporting this meeting? Get in contact:
olivia.wright@md-education.com

Agenda & Faculty

May 1, 2026 | Day 1  

07:00 AM
Registration Opens
08:00 AM
Industry Supported Independent Expert Discussion
08:45 AM
Coffee Break

Session I: Advanced EGFR Mutant NSCLC
Moderated by:

TBD

KOL TBD
TBD

09:05 PM
Competing First-Line Strategies: MARIPOSA and FLAURA2

XL

Xiuning Le, MD
MD Anderson Cancer Center, Houston, TX
09:25 PM
Ivonescimab and Other Second Line Options
Liza-Villaruz-1
Liza Villaruz, MD
UPMC Hillman Cancer Center, Pittsburgh, PA
09:45 PM
Evolving Role of ADCs for EGFR+ NSCLC

ZP

Zosia Piotrowska, MD
Massachusetts General Hospital, Boston, MA
10:05 AM
Panel Discussion
10:25 AM
Coffee Break

Session II: Targeted Therapy in the Early Stage Setting
Moderated by:

TBD

TBD
TBD

10:45 AM
(Neo)adjuvant: Current, Future, Biomarkers

BH

Brian Henick,, MD
Columbia University Irving Medical Center, New York, NY
11:05 AM
Consolidation Post Chemoradiation
Narjust-Florez-1
Narjust Florez, MD
Dana-Farber Cancer Institute, Boston, MA
11:25 AM
MRD and ctDNA

BP

Bruna Pellini, MD
Baptist Health Miami Cancer Institute, Miami, FL 
11:45 AM
Panel Discussion
12:05 PM
Lunch Break + Faculty and Fellow Photo
12:55 PM
Industry Supported Independent Expert Discussion

Session III: Early-stage immunotherapy
Moderated by:

TBD

TBD
TBD

1:40 PM
Neoadjuvant and Perioperative Standards
Tina-Cascone-1
Tina Cascone, MD
MD Anderson Cancer Center, Houston, TX
2:00 PM
Future Directions for Perioperative Care
Ryan-Gentzler-1
Ryan Gentzler, MD
University of Virginia, School of Medicine, Charlottesville, VA
2:20 PM
Novel Strategies in Unresectable NSCLC
Balazs-Halmos-1
Balazs Halmos, MD
Albert Einstein College of Medicine, Bronx, NY
2:40 PM
Panel Discussion
3:00 PM
Coffee Break
3:20 PM
Industry Supported Independent Expert Discussion

Session IV: Small Cell Lung Cancer (ES/LS)
Moderated by:

TBD

TBD
TBD

4:05 PM
Current Standards for First Line and Maintenance
Alissa-Cooper-1
Alissa Cooper, MD
Dana-Farber Cancer Institute, Boston, MA
4:25 PM
Integrating T-Cell Engagers for SCLC
Hossein-Borghaei-1
Hossein Borghaei, MD
Fox Chase Cancer Center, Temple Health, Philadelphia, PA
4:45 PM
Defining the Role for ADCs and Bispecifics

MA

Mariam Alexander, MD
MUSC Health, Charleston, SC
5:05 PM
Panel Discussion
5:25 PM
Adjourn

Agenda & Faculty

May 2, 2026 | Day 2

07:00 AM
Registration Opens
08:00 AM
Industry Supported Independent Expert Discussion
08:45 AM
Coffee Break

Session V: Mutations and Overexpression
Moderated by:

TBD

KOL TBD
TBD

9:05 AM
KRAS G12C - Current, Future

MJ

Melissa Johnson, MD
Sarah Cannon Research Institute, Nashville, TN
9:25 AM
HER2: ADC vs TKI
Mark-Kris-1
Mark Kris, MD
Memorial Sloan Kettering Cancer Center, New York, NY
9:45 AM
BRAF & MET
Ticiana-Leal-1
Ticiana Leal, MD
Emory Winship Cancer Institute, Atlanta, GA
10:05 AM
Panel Discussion
10:25 AM
Coffee Break

Session VI: Immunotherapy in Advanced NSCLC
Moderated by:

TBD

TBD
TBD

10:45 AM
Current Standards
Justin-Gainor-1
Justin Gainor, MD
Massachusetts General Hospital, Boston, MA
11:05 AM
Bispecifics and ADCs
Jonathan-Riess-1
Jonathan Riess, MD
UC Davis Comprehensive Cancer Center, Sacramento, CA
11:25 AM
Biomarker Development

JR

Julia Rotow, MD
Dana-Farber Cancer Institute, Boston, MA 
11:45 AM
Panel Discussion
12:05 PM
Lunch Break
12:55 PM
Industry Supported Independent Expert Discussion

Session VII: Fusions
Moderated by:

TBD

TBD
TBD

1:40 PM
ALK

SG

Shirish Gadgeel, MD
Henry Ford Health, Detroit, MI
2:00 PM
ROS1
Jessica-Lin-1
Jessica Lin, MD
Massachusetts General Hospital, Boston, MA
2:20 PM
RET, NTRK, NRG1
Christine-Lovly-1
Christine M. Lovly, MD, PhD, FASCO
City of Hope, Duarte, CA
2:40 PM
Panel Discussion
3:00 PM
Coffee Break
3:20 PM
Industry Supported Independent Expert Discussion

Session VIII: Other Thoracic Tumors
Moderated by:

TBD

TBD
TBD

4:05 PM
Mesothelioma
Melina-Marmarelis-1
Melina Marmarelis, MD
Penn Medicine, Philadelphia, PA
4:25 PM
Thymic Malignancies
Chul-Kim-1
Chul Kim, MD
Georgetown University, Washington, DC
4:45 PM
Pulmonary Neuroendocrine
Lyudmila-Bazhenova-1
Lyudmila Bazhenova, MD
UC San Diego Health, CA
5:05 PM
Panel Discussion
5:25 PM
Adjourn

Olivia Wright
Project Manager

How long has Olivia Wright been in the business?

Olivia Wright has been with MD Education since 2025.

About Olivia Wright

As a Project Manager, I support the delivery of educational events and projects at MD Education, working closely with the project management team to ensure smooth coordination and consistently high-quality execution. With a strong background in organisation and communication, I take pride in maintaining a detail-oriented approach to my work. I am committed to delivering to a high standard and value the opportunity to be part of a team dedicated to advancing clinical education.

Olivia-Wright